Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$536.87 USD
+5.01 (0.94%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $536.96 +0.09 (0.02%) 5:28 PM ET
2-Buy of 5 2
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$536.87 USD
+5.01 (0.94%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $536.96 +0.09 (0.02%) 5:28 PM ET
2-Buy of 5 2
C Value C Growth A Momentum B VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Thermo Fisher (TMO) to Buy Patheon, Expand in Biopharma
by Zacks Equity Research
Thermo Fisher Scientific Inc. (TMO), a leading scientific instrument maker, recently agreed to acquire Netherlands-based Patheon N.V.
Thermo Fisher (TMO) Tops Q1 Earnings, Sales, Raises Guidance
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) reported better-than-expected first-quarter 2017 earnings results.
Thermo Fisher (TMO) Beats on Q1 Earnings & Sales Estimates
by Zacks Equity Research
Currently, Thermo Fisher has a Zacks Rank #3 (Hold) but that could change following its promising first-quarter 2017 earnings report which has just released.
Thermo Fisher (TMO) Up 4.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Will Thermo Fisher (TMO) Pull a Surprise in Q1 Earnings?
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) is scheduled to report first-quarter 2017 results before the opening bell on Apr 26.
Should Value Investors Consider Thermo Fisher (TMO) Stock?
by Zacks Equity Research
Let's see if Thermo Fisher Scientific, Inc. (TMO) stock is a good choice for value-oriented investors right now from multiple angles.
Trump, Biogen and Amgen Hammer Healthcare ETFs
by Sweta Killa
After making a strong comeback in February, the U.S. healthcare sector again witnessed some pain in the last couple of sessions.
Thermo Fisher Poised on Innovation, Global Growth Amid Woes
by Zacks Equity Research
On Mar 17, 2017, we issued an updated research report on Thermo Fisher Scientific Inc. (TMO).
The Zacks Analyst Blog Highlights: Johnson & Johnson, PayPal, Thermo Fisher, Celgene and American Airlines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, PayPal, Thermo Fisher, Celgene and American Airlines
Top Research Reports for February 1, 2017
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), PayPal (PYPL) and Thermo Fisher (TMO).
Thermo Fisher (TMO) Q4 Earnings Beat, Organic Sales Flat
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) reported better-than-expected fourth-quarter and full-year 2016 earnings results.
Thermo Fisher (TMO): Tops Q4 Earnings, Misses Revenues
by Zacks Equity Research
Thermo Fisher (TMO) has posted earnings which has beaten the Zacks Consensus Estimate but its revenues missed the mark.
4 Stocks with Great Earnings Charts
by Tracey Ryniec
Companies that beat nearly every quarter are earnings all-stars.
Medical Products Stocks' Earnings on Jan 31: ZBH, TMO, ABC
by Zacks Equity Research
Let's take a look at the major Medical Product stocks slated to release their earnings results on tomorrow.
Will Thermo Fisher (TMO) Beat Earnings Estimates in Q4?
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) is scheduled to report fourth-quarter and full-year 2016 results before the opening bell on Jan 31.
Top Research Reports for January 12, 2017
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Goldman Sachs (GS), Canadian National Railway (CNI) and Boeing (BA).
5 GARP Stocks that Should Grace Your Portfolio
by Zacks Equity Research
Growth at a reasonable price or GARP is speculated to offer investors a chance to get hold of stocks that are undervalued but have impressive growth potential.
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, Arch Capital Group, IPG Photonics, AngioDynamics and Express Scripts Holding
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, Arch Capital Group, IPG Photonics, AngioDynamics and Express Scripts Holding
Postive Bank Results This Earnings Season
by Sheraz Mian
Plenty of results are still to come, but the big banks are showing a notable improvement in their earnings power.
New Research Reports for Tesla, Exxon, JNJ & Others
by Sheraz Mian
Today's must-read reports are for Exxon Mobil (XOM), Johnson & Johnson (JNJ) and Tesla (TSLA).
Top 7 Research Reports for July 29, 2016
by Sheraz Mian
Today's must-read reports are for Amgen (AMGN), JPMorgan (JPM) and Mondelez (MDLZ).
4 Medical Instrument Stocks to Bet on This Earnings Season
by Zacks Equity Research
The medical instrument sector holds a lot of promise at this moment.
Rush in Medical Device Investments: Should You Buy These Stocks?
by Zacks Equity Research
Coming to the weakest links in the MedTech sector, we advise investors against names that offer little growth/opportunity in the near term.
Should You Buy Evolving Trends in Medical Devices?
by Zacks Equity Research
Given the U.S. government's pushback on tax-dodging, we expected some sloth to creep into the medical device space as far as M&As are concerned. But to our surprise, M&A activity worldwide has remained fairly stable.